BioSpace News Archive

Inozyme Pharma, Inc. (Nasdaq: INZY) today announced the publication of an article titled, “ENPP1 Deficiency: A clinical update on the relevance of individual variants using a locus-specific database,” in Human Mutation.

Rakovina Therapeutics Inc. is pleased to announce the presentation of new data during the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, which was held in Barcelona Spain October 26-28, 2022.

Clene Inc. and Clene Nanomedicine Inc. announced that it has entered into a securities purchase agreement with certain existing stockholders, including existing stockholders affiliated with Clene’s board of directors, for the purchase and sale of 10,723,926 shares of the Company’s common stock at a purchase price per share of $1.01, priced at-the-market based on the October 28, 2022 closing stock price, in a registered direct offering.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association Scientific Sessions 2022 taking place in Chicago, IL from November 5, 2022 - November 7, 2022.

Daxor Corporation, the global leader in blood volume measurement technology, announces it will be attending the American Heart Association Scientific Sessions at McCormick Place Convention Center in Chicago, IL from November 5-7th, 2022.

The North Florida Region of The Leukemia & Lymphoma Society and Wawa and The Wawa Foundation have joined forces to end blood cancer, a disease diagnosed every 180 seconds in the U.S.

Enosis Therapeutics has partnered with OVID Clinics and the MIND Foundation to implement the world’s first in-clinic application of VR with Psychedelic-Assisted therapy.

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022.

TherapeuticsMD, Inc. announced today that it received an additional $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced the publication of two additional major clinical studies relating to its lead product, IsoPSA, for prostate cancer.